WALTHAM, Mass., March 27, 2012 (GLOBE NEWSWIRE) -- On-Q-ity, a life sciences company dedicated to providing the most accurate and actionable information possible across multiple cancers to enhance drug development and patient outcomes, today announced that it will be presenting data on both its circulating tumor cell (CTC) and biomarker programs at the Tucson Symposium, an annual gathering of scientific collaborators exploring new options in the pathology of cancer, sponsored by Ventana Medical Systems and held at the Westward Look Resort March 27-29.
On-Q-ity scientists will be presenting research on its lead program, the CTC platform, a novel technology featuring a dual capture capability, high capture rate and customized imaging that may provide critical information to clinical researchers and physicians.
The company also will be discussing data involving its early biomarker program in detecting the status of chemotherapy-treated breast cancer patients.
Both posters will be presented during the three-day meeting:
| Poster 07 |
| Detecting Circulating Tumor Cells From a Microfluidic Chip Using a Customized Imaging Platform |
| Poster 27 |
| TOP2A Status in Chemotherapy-treated Breast Cancer Patients Using FISH in Cytokeratin-Positive Cells |
About On-Q-ity
On-Q-ity is a life sciences company focused on novel circulating tumor cell (CTC) capture and characterization. We are developing products and services for clinical researchers and physicians that will enhance decision-making across multiple cancer types. On-Q-ity envisions a time when cancer is transformed from a fatal to chronic disease via CTC technology, further enabling the promise of personalized medicine. Our goals are to increase the success of oncology drug development, improve patient treatment outcomes and increase survival rates. Headquartered in Waltham, MA, On-Q-ity is currently funded by Atlas Venture, Mohr Davidow and Physic Ventures. For more information visit our website: www.On-Q-ity.com.